AU1735801A - Antibody against human kgfr - Google Patents

Antibody against human kgfr

Info

Publication number
AU1735801A
AU1735801A AU17358/01A AU1735801A AU1735801A AU 1735801 A AU1735801 A AU 1735801A AU 17358/01 A AU17358/01 A AU 17358/01A AU 1735801 A AU1735801 A AU 1735801A AU 1735801 A AU1735801 A AU 1735801A
Authority
AU
Australia
Prior art keywords
kgfr
antibody against
against human
human
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU17358/01A
Inventor
Takehiko Koji
Mitsuru Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nichirei Corp
Original Assignee
Nichirei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nichirei Corp filed Critical Nichirei Corp
Publication of AU1735801A publication Critical patent/AU1735801A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU17358/01A 2000-04-17 2000-12-11 Antibody against human kgfr Abandoned AU1735801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-115253 2000-04-17
JP2000115253A JP2001302699A (en) 2000-04-17 2000-04-17 Antibody against human kgfr
PCT/JP2000/008736 WO2001079266A1 (en) 2000-04-17 2000-12-11 Antibody against human kgfr

Publications (1)

Publication Number Publication Date
AU1735801A true AU1735801A (en) 2001-10-30

Family

ID=18626937

Family Applications (1)

Application Number Title Priority Date Filing Date
AU17358/01A Abandoned AU1735801A (en) 2000-04-17 2000-12-11 Antibody against human kgfr

Country Status (3)

Country Link
JP (1) JP2001302699A (en)
AU (1) AU1735801A (en)
WO (1) WO2001079266A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2546254C9 (en) 2008-11-07 2015-07-10 Гэлэкси Биотех, Ллс. Monoclonal antibodies to fibroblast growth factor receptor 2
RU2015137610A (en) 2013-03-06 2017-04-10 Дженентек, Инк. METHODS FOR TREATMENT AND PREVENTION OF DRUG RESISTANCE OF MALIGNANT TUMORS
HUE058243T2 (en) 2013-08-01 2022-07-28 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
BR112018010410A8 (en) 2015-11-23 2019-02-26 Five Prime Therapeutics Inc method for treating cancer in a subject, composition and methods of increasing the number of nk cells and increasing the number of one or more pd-11 positive cells
CN109844537B (en) * 2016-09-27 2022-06-24 高地和群岛大学 Antigen biomarkers
KR20200006538A (en) 2017-05-16 2020-01-20 파이브 프라임 테라퓨틱스, 인크. Anti-FGFR2 Antibody in Combination with Chemotherapy in Cancer Treatment

Also Published As

Publication number Publication date
JP2001302699A (en) 2001-10-31
WO2001079266A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2002256895A1 (en) Anti-TRAIL-R antibodies
AU2001262847A1 (en) Language-understanding
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2002365649A1 (en) Anti-dota antibody
AU2001279754A1 (en) Indoloquinazolinones
AU2001264304A1 (en) Illuminator
AU2001285886A1 (en) 2-guanidino-4-aryl-quinazoline
AU2001265871A1 (en) Substituted sulfonylaminopyrimidines
AU2001258924A1 (en) Microsatellite-aflp
AU2001286721A1 (en) Human interleukin-four induced protein
AU2001258255A1 (en) Substituted benzoylcyclohexenones
AU2001254731A1 (en) Substituted phenyluracils
AU2002227925A1 (en) Human beta-defensin-3
AU1735801A (en) Antibody against human kgfr
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors
AU2001291876A1 (en) Triazolo-epothilones
AU2002221132A1 (en) Novel antibody
AU2001244863A1 (en) Apoptin-associating protein
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001260192A1 (en) Glycinamides
AU2001284173A1 (en) Calycins

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase